http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA#Head http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA#assertion http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA#provenance http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA#pubinfo http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA#assertion http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object https://identifiers.org/MONDO:0001945 http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/CHEBI:3182 http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA#association http://www.w3.org/2000/01/rdf-schema#label Bromocriptine mesylate tablets are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson's disease. As adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor), bromocriptine mesylate therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa, those who are beginning to deteriorate (develop tolerance) to levodopa therapy, and those who are experiencing "end of dose failure" on levodopa therapy. http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA#association https://w3id.org/biolink/vocab/provided_by NeuroDKG http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA#association https://w3id.org/biolink/vocab/publications https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93a0696b-b261-4262-9e06-f3180b419f8f http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA#association https://w3id.org/biolink/vocab/relation https://w3id.org/um/neurodkg/SymptomaticReliefIndication https://identifiers.org/CHEBI:3182 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug https://identifiers.org/MONDO:0001945 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA#provenance http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA#pubinfo http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA#sig http://purl.org/nanopub/x/hasSignature ZHyrCk2z7qXvlzKEAzZQfFVAnc2w0z+nW4bse6zUIMp2SCax3AqnRRlqQAiORr37W9rnr7DwxLMi3HdsOIbMa9rtLKEFBUBQYiwXmG70Yy80Yp5o/9oJG1YUSL7QfmuLA5OWq3UOgreM1u11v6GYXMi6oEy5HV1cadB6O59EgC0= http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA http://purl.org/dc/terms/created 2021-03-28T20:10:59.894+02:00 http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAdzZfNP3FR9iEtT0sOp4die14iSu2iU8pUU8efN5VJeA https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RA59AEpaWRaR9sjdA0-n4zaQWdiZ6--iGafMrjrDAOheI